Indoco Remedies (INDOCO) Resumen de Acciones
Indoco Remedies Limited fabrica, comercializa y vende fórmulas e ingredientes farmacéuticos activos en la India y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 2/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
INDOCO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Competidores de Indoco Remedies Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | ₹251.91 |
| Máximo en las últimas 52 semanas | ₹348.00 |
| Mínimo de 52 semanas | ₹162.19 |
| Beta | 0.55 |
| Cambio en 1 mes | 8.13% |
| Variación en 3 meses | 14.74% |
| Cambio de 1 año | -25.68% |
| Variación en 3 años | -24.08% |
| Variación en 5 años | -43.91% |
| Variación desde la OPV | 379.22% |
Noticias y actualizaciones recientes
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.Recent updates
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook
Analysts have raised their price target on Indoco Remedies from ₹207 to ₹250, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that together suggest a higher estimated fair value for the stock. What's in the News A board meeting is scheduled for April 30, 2026, to consider transferring Indoco Remedies' ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited, on terms set out in a business transfer agreement (Key Developments).Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Key Insights Indoco Remedies will host its Annual General Meeting on 11th of September Total pay for CEO Sundeep...Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
The Indoco Remedies Limited ( NSE:INDOCO ) share price has done very well over the last month, posting an excellent...Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Indoco Remedies Limited ( NSE:INDOCO ) shares have had a horrible month, losing 25% after a relatively good period...
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a mediocre week for Indoco Remedies Limited ( NSE:INDOCO ) shareholders, with the stock dropping 11% to ₹304...Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
A lackluster earnings announcement from Indoco Remedies Limited ( NSE:INDOCO ) last week didn't sink the stock price...Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Indoco Remedies Limited ( NSE:INDOCO ), which a week ago released some...Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Performance at Indoco Remedies Limited ( NSE:INDOCO ) has been reasonably good and CEO Sundeep Bambolkar has done a...Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Rentabilidad de los accionistas
| INDOCO | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | -1.2% | 2.2% | 1.9% |
| 1Y | -25.7% | 12.3% | -1.3% |
Rentabilidad vs. Industria: Los resultados de INDOCO fueron inferiores a los de la industria Indian Pharmaceuticals, que obtuvo un rendimiento del 12.3% el año pasado.
Rentabilidad vs. Mercado: INDOCO obtuvo unos resultados inferiores a los del mercado Indian, que fueron del -1.3% el año pasado.
Volatilidad de los precios
| INDOCO volatility | |
|---|---|
| INDOCO Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.8% |
Precio estable de las acciones: El precio de las acciones de INDOCO ha sido volátil durante los últimos 3 meses en comparación con el mercado Indian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de INDOCO(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Indian.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1945 | 6,000 | Sundeep Bambolkar | www.indoco.com |
Indoco Remedies Limited fabrica, comercializa y vende fórmulas e ingredientes farmacéuticos activos en la India y a escala internacional. Ofrece productos estomatológicos, gastrointestinales, respiratorios, antiinfecciosos, vitaminas/minerales/nutrientes, oftalmológicos/ontológicos, dermatológicos, urológicos, antidiabéticos, ginecológicos, para el control del estilo de vida, analgésicos y cardíacos. La empresa también suministra genéricos de marca que comprenden comprimidos analgésicos y preparados tópicos; antihipertensivos; suplementos proteicos; comprimidos y jarabes multivitamínicos; comprimidos, jarabes e inyectables antibióticos; polvos de rehidratación oral; antiácidos; y antihistamínicos, así como cremas antihemorroidales y preparados de calcio.
Resumen de fundamentos de Indoco Remedies Limited
| Estadísticas fundamentales de INDOCO | |
|---|---|
| Capitalización bursátil | ₹23.04b |
| Beneficios(TTM) | -₹951.50m |
| Ingresos (TTM) | ₹18.45b |
¿Está INDOCO sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de INDOCO | |
|---|---|
| Ingresos | ₹18.45b |
| Coste de los ingresos | ₹5.42b |
| Beneficio bruto | ₹13.04b |
| Otros gastos | ₹13.99b |
| Beneficios | -₹951.50m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 28, 2026
| Beneficios por acción (BPA) | -10.31 |
| Margen bruto | 70.64% |
| Margen de beneficio neto | -5.16% |
| Ratio deuda/patrimonio | 111.1% |
¿Cómo se ha desempeñado INDOCO a largo plazo?
Ver rendimiento histórico y comparativaDividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/16 12:50 |
| Precio de las acciones al final del día | 2026/07/16 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Indoco Remedies Limited está cubierta por 13 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |